Results 1 to 10 of about 3,267 (206)

Actinomycosis in a Mucosal Lesion on a Created Perioral Dimple: A Case Report [PDF]

open access: yesArchives of Aesthetic Plastic Surgery, 2017
Facial dimple creation is a simple surgical procedure. Nonetheless, several complications can occur. Actinomycosis is a rare chronic granulomatous infection caused by Actinomyces species.
Ui Geon Kim   +3 more
doaj   +1 more source

Advances in Immunosuppressive Agents Based on Signal Pathway

open access: yesFrontiers in Pharmacology, 2022
Immune abnormality involves in various diseases, such as infection, allergic diseases, autoimmune diseases, as well as transplantation. Several signal pathways have been demonstrated to play a central role in the immune response, including JAK/STAT, NF ...
Zhiqing Xu, Zhiqing Xu, Ming Chu
doaj   +1 more source

Immunosuppressive therapy in non-infections uveitis and retinovasculitis

open access: yesOftalʹmologiâ, 2014
Purpose: to evaluate the efficacy and safety of the immunosuppressive therapy for severe forms of non-infections uveitis and retinovasculitis.Methods: 107 patients (62 males and 45 females aged 9 to 54 years) who received low dose methotrexate — 7.5-20 ...
E. A. Drozdova
doaj   +3 more sources

New-onset epilepsy in a patient with myelin oligodendrocyte glycoprotein antibodies [PDF]

open access: yesEncephalitis, 2021
In the literature, several adult cases with myelin oligodendrocyte glycoprotein (MOG) antibodies (Abs)-associated disorders have been reported to have seizure and acute disseminated encephalomyelitis (ADEM) as the main clinical manifestations, but the ...
Hansol Im, Taewon Kim
doaj   +1 more source

Infiltrative cardiomyopathies. Report of a case of cardiac sarcoidosis

open access: yesIatreia, 2017
Sarcoidosis is characterized by the presence of non-caseating granulomas that may affect any organ. Heart involvement manifests as cardiomyopathy. Frequency of cardiac involvement in sarcoidosis is around 30 %, but only 5 % of such cases are symptomatic.
Muñoz-Ortiz, Édison   +3 more
doaj   +1 more source

Rituximab: A Magic Bullet for Pemphigus [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2017
Introduction: Pemphigus, an autoimmune disease, was fatal before the era of corticosteroids. With the advent of steroids, mortality decreased but morbidity was present due to the side effects of high dose steroids.
V. Anandan   +4 more
doaj   +1 more source

Off-label use of rituximab in dermatology: pemphigus treatment [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2013
Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis.
Lislaine Bomm   +4 more
doaj   +1 more source

Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials

open access: yesBMC Nephrology, 2019
Background Immunosuppressive agents have been widely used in the treatment of IgA nephropathy (IgAN), but the efficacy and safety remain controversial.
Zheng Zhang   +3 more
doaj   +1 more source

New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2015
Everolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is being increasingly applied in oncology and solid organ transplantation. Oral ulcers are a frequent side effect associated with this immunosupressor.
Victor Pavan Pasin   +5 more
doaj   +1 more source

Safety and effectiveness of mycophenolate mofetil associated with tacrolimus for liver transplantation immunosuppression: a systematic review and meta-analysis of randomized controlled trials [PDF]

open access: yesClinics, 2021
A combination of immunosuppressants may improve outcomes due to the synergistic effect of their different action mechanisms. Currently, there is no consensus regarding the best immunosuppressive protocol after liver transplantation.
Francisco Tustumi   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy